Brazil aims to man­u­fac­ture its own cell ther­a­pies — at a frac­tion of the cur­rent cost

Brazil’s Min­istry of Health is work­ing with a US non­prof­it to lo­cal­ly man­u­fac­ture CAR-T ther­a­pies and po­ten­tial­ly oth­er cell and gene ther­a­pies at a much low­er cost.

The goal is to pro­vide cell ther­a­py free of charge to pa­tients while charg­ing Brazil’s health sys­tem around $35,000 a dose, which is rough­ly one-tenth of the cost in Eu­rope and an even small­er frac­tion of US costs.

CAR-T ther­a­pies have trans­formed the treat­ment of cer­tain blood can­cers, but a course of treat­ment can cost near­ly $500,000 in the US, and wide­spread ac­cess has been plagued by lim­it­ed sup­ply and com­plex man­u­fac­tur­ing process­es.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER